Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)

NACompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Cirrhosis
Interventions
DRUG

Propranolol

Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

DRUG

Placebo

Placebo tablets given two times daily.

Trial Locations (1)

110002

Department of Gastroenterology, G B Pant Hospital, New Delhi

All Listed Sponsors
lead

Govind Ballabh Pant Hospital

OTHER_GOV

NCT00772057 - Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT) | Biotech Hunter | Biotech Hunter